As of November 28, 2022, the shares of the company "LAVIPHARM S.A." (GRS246003008) are traded on the ATHEX ex-rights in terms of 10.01868413773180 new (CR) shares for every 1 old (CR) share held - with issue of 170,588,235 new CR shares - at an issue price of €0.34 per share. The rights' trading period is set from December 1, 2022, to December 9, 2022 (included). The rights' subscription period is set from December 1, 2022, to December 14, 2022 (included).

It is clarified, according to article 2.6.3. of the ATHEX Rulebook and to decisions No 22 & 26 of the ATHEX BoD, as in effect, that the fluctuation price limits of the share price only for the trading session on November 28, 2022, are set as follows: +20% at the closing share price of the ATHEX last trading session (25/11/2022): €0.3680 and -20% at the adjusted start share price: €0.3420.

For convenience, the formula for the calculation of the adjusted start share price is given below, which results from Decision 26 of the ATHEX BoD and is applicable to every Share Capital Increase with a rights' issue, in favour of the old shareholders of the company:

Hence, the following can be deduced from the above:

Adjusted share price: €0.3420

Closing share price of the ATHEX last trading session (25/11/2022): €0.3680

Maximum Trading limit +20% : €0.4400

Minimum Trading limit  -20%  : €0.2740

According to the above, and taking into consideration that in the system ΟΑΣΗΣ (the Advanced Electronic & Automated System for Securities Trading of ATHEX) the start share price - in this case - is the adjusted share price, the maximum and minimum trading limits are formed as follows:

Start share price: €0.3420

Ceiling  +28.66% : €0.4400

Floor           -20% : €0.2740